Oscar Health Q3 revenue misses estimates, reaffirms guidance

Oscar Health

06/11/2025 11:17

Overview

Oscar Health Q3 revenue rises but misses analyst expectations

Adjusted EBITDA for Q3 beats analyst estimates, despite net loss

Company reaffirms full-year 2025 guidance and settles part of 2031 notes

Outlook

Oscar Health reaffirms 2025 revenue guidance of $12.0 bln to $12.2 bln

Company expects 2025 medical loss ratio between 86.0% and 87.0%

Oscar Health projects 2025 SG&A expense ratio between 17.1% and 17.6%

Result Drivers

HIGHER MEMBERSHIP - Revenue growth driven by increased membership, despite missing analyst expectations

INCREASED MARKET MORBIDITY - Higher medical loss ratio due to increased average market morbidity, impacting financial results

COST MANAGEMENT - SG&A expense ratio decreased due to greater fixed cost leverage and disciplined cost management

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$2.99 bln
$3.08 bln (8 Analysts)
Q3 Net Income
-$137.45 mln
Q3 Adjusted EBITDA
Beat
-$101.45 mln
-$102.94 mln (5 Analysts)
Q3 Operating Expenses
$3.12 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and 5 "sell" or "strong sell"

The average consensus recommendation for the life & health insurance peer group is "buy."

Wall Street's median 12-month price target for Oscar Health Inc is $13.00, about 31% below its November 5 closing price of $17.03

Press Release: ID:nBw1jpVsWa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)